Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
Condition(s):Differentiated Thyroid Cancer; GenderLast Updated:March 29, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Differentiated Thyroid Cancer; GenderLast Updated:March 29, 2023Recruiting
Condition(s):Hepatocellular Carcinoma Non-resectableLast Updated:June 13, 2023Not yet recruiting
Condition(s):Hepatocellular CarcinomaLast Updated:November 18, 2023Recruiting
Condition(s):Liver TumorLast Updated:September 26, 2022Recruiting
Condition(s):Renal Cell CarcinomaLast Updated:May 12, 2023Recruiting
Condition(s):Cadonilimab and LenvatinibLast Updated:January 22, 2024Not yet recruiting
Condition(s):Hepatocellular CarcinomaLast Updated:March 29, 2023Recruiting
Condition(s):Lenvatinib TreatmentLast Updated:March 20, 2024Recruiting
Condition(s):Unresectable Hepatocellular Carcinoma; Pembrolizumab; Lenvatinib; Stereotactic Body RadiotherapyLast Updated:March 2, 2023Not yet recruiting
Condition(s):Melanoma, UvealLast Updated:August 14, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.